Tirzepatide (Mounjaro, Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist used for type 2 diabetes and chronic weight management
Fatigue some people feel a low-energy day after their injection
Because you're in a caloric deficit (or should be)
Monitoring and follow-ups Schedule ongoing visits with your healthcare provider to monitor progress, manage side effects, and adjust the dosage as needed
The gradual dose-escalation schedule used in medical weight losstypically starting at 0.25 mg and increasing at intervals set by your prescriber, commonly about every 4 weeksgives your body time to adapt to each level before introducing higher doses
The brand has lined up nationwide distribution with Walmart as well as expanded its offerings in CVS, Kroger, Shoprite, Fresh Market and QuickTrip chains, among others